Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs*

Overview

Journal Angew Chem Int Ed Engl

Specialty Chemistry

Date 2021 Sep 28

PMID 34581471

Citations 12

Authors

Carlos A Ramos-Guzman

J Javier Ruiz-Pernia

Inaki Tunon

Affiliations

Soon will be listed here.

Abstract

We present the results of classical and QM/MM simulations for the inhibition of SARS-CoV-2 3CL protease by a hydroxymethylketone inhibitor, PF-00835231. In the noncovalent complex the carbonyl oxygen atom of the warhead is placed in the oxyanion hole formed by residues 143 to 145, while P1-P3 groups are accommodated in the active site with interactions similar to those observed for the peptide substrate. According to alchemical free energy calculations, the P1' hydroxymethyl group also contributes to the binding free energy. Covalent inhibition of the enzyme is triggered by the proton transfer from Cys145 to His41. This step is followed by the nucleophilic attack of the Sγ atom on the carbonyl carbon atom of the inhibitor and a proton transfer from His41 to the carbonyl oxygen atom mediated by the P1' hydroxyl group. Computational simulations show that the addition of a chloromethyl substituent to the P1' group may lower the activation free energy for covalent inhibition.

Citing Articles

CHARMM-GUI for Protein-Ligand Docking of Multiple Reactive States along a Reaction Coordinate in Enzymes.

Suh D, Schwartz R, Gupta P, Zev S, Major D, Im W J Chem Theory Comput. 2025; 21(4):2118-2128.

PMID: 39950957 PMC: 11866752. DOI: 10.1021/acs.jctc.4c01691.

3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials.

Amorim V, Soares E, de Almeida Ferrari A, Merighi D, de Souza R, Guzzo C Viruses. 2024; 16(6).

PMID: 38932137 PMC: 11209289. DOI: 10.3390/v16060844.

Perspectives on Computational Enzyme Modeling: From Mechanisms to Design and Drug Development.

Nam K, Shao Y, Major D, Wolf-Watz M ACS Omega. 2024; 9(7):7393-7412.

PMID: 38405524 PMC: 10883025. DOI: 10.1021/acsomega.3c09084.

Anti-infection effects of heparin on SARS-CoV-2 in a diabetic mouse model.

Zhang Z, Zhang N, Lu X, Zhou M, Yan X, Gu W Zool Res. 2023; 44(6):1003-1014.

PMID: 37759335 PMC: 10802103. DOI: 10.24272/j.issn.2095-8137.2023.108.

Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches.

Shao Q, Xiong M, Li J, Hu H, Su H, Xu Y Chem Sci. 2023; 14(18):4681-4696.

PMID: 37181765 PMC: 10171076. DOI: 10.1039/d3sc00166k.

References

Dai W, Zhang B, Jiang X, Su H, Li J, Zhao Y . Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020; 368(6497):1331-1335. PMC: 7179937. DOI: 10.1126/science.abb4489. View

Hilgenfeld R . From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014; 281(18):4085-96. PMC: 7163996. DOI: 10.1111/febs.12936. View

Ramos-Guzman C, Ruiz-Pernia J, Tunon I . Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs*. Angew Chem Int Ed Engl. 2021; 60(49):25933-25941. PMC: 8653175. DOI: 10.1002/anie.202110027. View

Qiao J, Li Y, Zeng R, Liu F, Luo R, Huang C . SARS-CoV-2 M inhibitors with antiviral activity in a transgenic mouse model. Science. 2021; 371(6536):1374-1378. PMC: 8099175. DOI: 10.1126/science.abf1611. View

Solowiej J, Thomson J, Ryan K, Luo C, He M, Lou J . Steady-state and pre-steady-state kinetic evaluation of severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro cysteine protease: development of an ion-pair model for catalysis. Biochemistry. 2008; 47(8):2617-30. DOI: 10.1021/bi702107v. View

Hoffman R, Kania R, Brothers M, Davies J, Ferre R, Gajiwala K . Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J Med Chem. 2020; 63(21):12725-12747. DOI: 10.1021/acs.jmedchem.0c01063. View

Ramos-Guzman C, Ruiz-Pernia J, Tunon I . A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design. Chem Sci. 2021; 12(10):3489-3496. PMC: 8179461. DOI: 10.1039/d0sc04978f. View

de Vries M, Mohamed A, Prescott R, Valero-Jimenez A, Desvignes L, OConnor R . A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol. 2021; 95(7). PMC: 8139662. DOI: 10.1128/JVI.01819-20. View

Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L . Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020; 368(6489):409-412. PMC: 7164518. DOI: 10.1126/science.abb3405. View

10.

Drag M, Salvesen G . Emerging principles in protease-based drug discovery. Nat Rev Drug Discov. 2010; 9(9):690-701. PMC: 2974563. DOI: 10.1038/nrd3053. View

11.

Ramos-Guzman C, Ruiz-Pernia J, Tunon I . Multiscale Simulations of SARS-CoV-2 3CL Protease Inhibition with Aldehyde Derivatives. Role of Protein and Inhibitor Conformational Changes in the Reaction Mechanism. ACS Catal. 2021; 11(7):4157-4168. DOI: 10.1021/acscatal.0c05522. View

12.

Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y . Structure of M from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020; 582(7811):289-293. DOI: 10.1038/s41586-020-2223-y. View

13.

Ma C, Sacco M, Hurst B, Townsend J, Hu Y, Szeto T . Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020; 30(8):678-692. PMC: 7294525. DOI: 10.1038/s41422-020-0356-z. View

14.

Ramos-Guzman C, Ruiz-Pernia J, Tunon I . Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods. ACS Catal. 2021; 10:12544-12554. DOI: 10.1021/acscatal.0c03420. View

15.

Mondal D, Warshel A . Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of α-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2. Biochemistry. 2020; 59(48):4601-4608. PMC: 7688048. DOI: 10.1021/acs.biochem.0c00782. View

16.

Arafet K, Serrano-Aparicio N, Lodola A, Mulholland A, Gonzalez F, Swiderek K . Mechanism of inhibition of SARS-CoV-2 M by peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. Chem Sci. 2021; 12(4):1433-1444. PMC: 8179034. DOI: 10.1039/d0sc06195f. View

17.

Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z . The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A. 2003; 100(23):13190-5. PMC: 263746. DOI: 10.1073/pnas.1835675100. View

18.

Powers J, Asgian J, Ekici O, James K . Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev. 2002; 102(12):4639-750. DOI: 10.1021/cr010182v. View

19.

Swiderek K, Moliner V . Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 M by QM/MM computational methods. Chem Sci. 2021; 11(39):10626-10630. PMC: 8162313. DOI: 10.1039/d0sc02823a. View

20.

Menendez C, Bylehn F, Perez-Lemus G, Alvarado W, de Pablo J . Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease. Sci Adv. 2020; 6(37). PMC: 7486088. DOI: 10.1126/sciadv.abd0345. View